Expert Interview
Discussing the topline results of Mineralys Therapeutics' Launch-HTN and Advance-HTN trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
Ticker(s): MLYSInstitution: HCA Healthcare
- Cardiologist in practice for over 11 years.
- Currently manages 30 patients that have both nHCM and Chronic Stable Angina.
- Uses eplerenone and spirnolactone currently as 4th line option for hypertension
What is your experience with spironolactone or eplerenone?
Added By: wilson_adminHow much of a detriment is hyperkalemia as an AE for treatment-resistant hypertension?
Added By: wilson_adminHow do you think lorundrostat will be used commercially?
Added By: wilson_adminHow do you define uncontrolled versus treatment-resistant hypertension, and which patient population do you think would benefit more from Lorundrostat’s aldosterone synthase inhibition mechanism?
Added By: slingshot_insightsWhat are your thoughts on the hyperkalemia risk associated with Lorundrostat, including the appropriate cutoff level (5.5 vs. 6.0 mmol/L), symptom differences between levels, and potential factors causing variations in hyperkalemia rates across clinical trials?
Added By: slingshot_insightsHow do Lorundrostat’s blood pressure-lowering effects compare to MRAs like spironolactone, and do you believe it should be used before or after MRAs in the treatment sequence for resistant hypertension?
Added By: slingshot_insightsDo you think cardiovascular outcomes trials (CVOT) are necessary for Lorundrostat’s commercial success, and what percentage of patients achieving blood pressure control would make the drug clinically meaningful?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
